Código QR (código de barras bidimensional)

Observational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in Morocco

Abstract Background Trastuzumab, a recombinant humanized monoclonal antibody has demonstrated clinical benefits in women with human epidermal growth factor receptor type 2 (HER2)-positive breast cancer in early and metastatic disease settings. However, real-world data on trastuzumab biosimilars are...

ver descrição completa

Na minha lista:
Principais autores: Hassan Errihani, Narjiss Berrada, Meryem El Bachiri, Hassan Jouhadi, Omar Kabbaj, Mouna Bourhafour, Abdellatif Benider, Mouna Khouchani, Ghizlane Belbaraka, Abdelkader Acharki, Redouane Samlali, Kunvar Harsh Upveja
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2026-04-01
coleção:BMC Cancer
Assuntos:
Biosimilar
Breast cancer
HER2-positive
Morocco
Trastuzumab
Acesso em linha:https://doi.org/10.1186/s12885-026-16005-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados